Retinoblastoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma.
|
16007192 |
2005 |
Retinoblastoma
|
0.090 |
AlteredExpression
|
disease |
LHGDN |
Taking into account the proliferation-promoting role of E2F3, implication of E2F3 in bladder and prostate cancer, and the translocation and overexpression of DEK in leukemia, we conclude that either DEK or E2F3 (or both) are targeted by the 6p22 gain in retinoblastoma.
|
16180235 |
2006 |
Retinoblastoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Taking into account the proliferation-promoting role of E2F3, implication of E2F3 in bladder and prostate cancer, and the translocation and overexpression of DEK in leukemia, we conclude that either DEK or E2F3 (or both) are targeted by the 6p22 gain in retinoblastoma.
|
16180235 |
2006 |
Retinoblastoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
For both bladder and prostate cancer, we have proposed that E2F3 protein overexpression may cooperate with removal of the E2F inhibitor retinoblastoma tumor suppressor protein (pRB) to drive cellular proliferation.
|
16909110 |
2007 |
Retinoblastoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).
|
17099872 |
2007 |
Retinoblastoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Our results demonstrated that some copy number changes thought to belong to early (MDM4 gain) or late stage (MYCN and E2F3 gain) of retinoblastoma are already present in retinoma at the same (for MDM4) or at lower (for MYCN and E2F3) copy number variation respect to retinoblastoma.
|
18785023 |
2008 |
Retinoblastoma
|
0.090 |
Biomarker
|
disease |
LHGDN |
Our results demonstrated that some copy number changes thought to belong to early (MDM4 gain) or late stage (MYCN and E2F3 gain) of retinoblastoma are already present in retinoma at the same (for MDM4) or at lower (for MYCN and E2F3) copy number variation respect to retinoblastoma.
|
18785023 |
2008 |
Retinoblastoma
|
0.090 |
AlteredExpression
|
disease |
LHGDN |
Further, E2F3 also showed a significant overexpression compared to RB cell lines (p=0.01).
|
19190782 |
2009 |
Retinoblastoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Further, E2F3 also showed a significant overexpression compared to RB cell lines (p=0.01).
|
19190782 |
2009 |
Retinoblastoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
The results exhibit that Rb expression is lower in patients with bladder tumor, while E2F3 level is high.
|
27922689 |
2017 |
Retinoblastoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Characterization of mouse embryonic fibroblasts with this Rb-independent E2F3<sup>LQ</sup> mutation revealed that disrupting the Rb and E2F3 interaction increased cell proliferation, allowed cells to accumulate to higher density, and significantly altered expression of genes involved in metabolism, inflammation, immunity, and response to stress.
|
28979847 |
2017 |
Retinoblastoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
E2F3, a member of the E2F family, plays a critical role in cell cycle and proliferation by targeting downstream, retinoblastoma (RB) a tumor suppressor family protein.
|
31839743 |
2019 |